WO2001085202A3 - Electroporation for introduction of molecules into cells - Google Patents

Electroporation for introduction of molecules into cells Download PDF

Info

Publication number
WO2001085202A3
WO2001085202A3 PCT/GB2001/001970 GB0101970W WO0185202A3 WO 2001085202 A3 WO2001085202 A3 WO 2001085202A3 GB 0101970 W GB0101970 W GB 0101970W WO 0185202 A3 WO0185202 A3 WO 0185202A3
Authority
WO
WIPO (PCT)
Prior art keywords
skeletal muscle
mammal
antigen
injection site
electrodes
Prior art date
Application number
PCT/GB2001/001970
Other languages
French (fr)
Other versions
WO2001085202A2 (en
Inventor
Iacob Mathiesen
Stig Tollefsen
Original Assignee
Electrofect As
Iacob Mathiesen
Stig Tollefsen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/055,084 external-priority patent/US6110161A/en
Application filed by Electrofect As, Iacob Mathiesen, Stig Tollefsen filed Critical Electrofect As
Priority to EP01928065A priority Critical patent/EP1280550A2/en
Priority to AU54932/01A priority patent/AU5493201A/en
Publication of WO2001085202A2 publication Critical patent/WO2001085202A2/en
Publication of WO2001085202A3 publication Critical patent/WO2001085202A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36003—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation of motor muscles, e.g. for walking assistance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36017—External stimulators, e.g. with patch electrodes with leads or electrodes penetrating the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides a method of eliciting an immune system response in a mammal, which method comprises: injecting a first antigen into a first injection site in skeletal muscle in said mammal; optionally injecting a polynucleotide functionally encoding a second antigen into a second injection site in skeletal muscle in said mammal; positioning electrodes in said skeletal muscle such that current travelling between said electrodes passes through said first and/or second injection site; and electrically stimulating said skeletal muscle with an electrical current between said electrodes having a field strength in said skeletal muscle of from 10 to 300 V/cm whereby to assist in cellular uptake of said first antigen and/or said polynucleotide.
PCT/GB2001/001970 1997-04-03 2001-05-04 Electroporation for introduction of molecules into cells WO2001085202A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01928065A EP1280550A2 (en) 1997-04-03 2001-05-04 Electroporation for introduction of molecules into cells
AU54932/01A AU5493201A (en) 1997-04-03 2001-05-04 Method for introduction of molecules into cells

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US4259497P 1997-04-03 1997-04-03
US09/055,084 US6110161A (en) 1997-04-03 1998-04-03 Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
US09/565,140 US6261281B1 (en) 1997-04-03 2000-05-05 Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US09/565,140 2000-05-05
US09/899,561 US20020038112A1 (en) 1997-04-03 2001-07-05 Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US10/141,561 US6610044B2 (en) 1997-04-03 2002-05-07 Method for genetic immunization
US10/620,271 US6958060B2 (en) 1997-04-03 2003-07-14 Method for muscle delivery of drugs, nucleic acids and other compounds

Publications (2)

Publication Number Publication Date
WO2001085202A2 WO2001085202A2 (en) 2001-11-15
WO2001085202A3 true WO2001085202A3 (en) 2002-03-28

Family

ID=35910568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/001970 WO2001085202A2 (en) 1997-04-03 2001-05-04 Electroporation for introduction of molecules into cells

Country Status (4)

Country Link
US (6) US6261281B1 (en)
EP (1) EP1280550A2 (en)
AU (1) AU5493201A (en)
WO (1) WO2001085202A2 (en)

Families Citing this family (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993434A (en) * 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5702359A (en) * 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US20040229363A1 (en) * 1998-06-24 2004-11-18 Ed Nolan High efficiency transfection based on low electric field strength, long pulse length
KR20040099264A (en) * 2002-01-18 2004-11-26 이노비오 에이에스 Bispecific antibody dna constructs for intramuscular administration
JP2005530695A (en) * 2002-02-15 2005-10-13 ザイコス インク． Electroporation method for introducing physiologically active substances into cells
US7245963B2 (en) * 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) * 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7617005B2 (en) 2002-04-08 2009-11-10 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US20140018880A1 (en) 2002-04-08 2014-01-16 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7653438B2 (en) 2002-04-08 2010-01-26 Ardian, Inc. Methods and apparatus for renal neuromodulation
US9308043B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for monopolar renal neuromodulation
US7162303B2 (en) 2002-04-08 2007-01-09 Ardian, Inc. Renal nerve stimulation method and apparatus for treatment of patients
US8175711B2 (en) 2002-04-08 2012-05-08 Ardian, Inc. Methods for treating a condition or disease associated with cardio-renal function
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
US7853333B2 (en) 2002-04-08 2010-12-14 Ardian, Inc. Methods and apparatus for multi-vessel renal neuromodulation
US20080213331A1 (en) 2002-04-08 2008-09-04 Ardian, Inc. Methods and devices for renal nerve blocking
US8347891B2 (en) 2002-04-08 2013-01-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for performing a non-continuous circumferential treatment of a body lumen
US9636174B2 (en) 2002-04-08 2017-05-02 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US20070135875A1 (en) 2002-04-08 2007-06-14 Ardian, Inc. Methods and apparatus for thermally-induced renal neuromodulation
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8145317B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods for renal neuromodulation
US8131371B2 (en) 2002-04-08 2012-03-06 Ardian, Inc. Methods and apparatus for monopolar renal neuromodulation
US7620451B2 (en) 2005-12-29 2009-11-17 Ardian, Inc. Methods and apparatus for pulsed electric field neuromodulation via an intra-to-extravascular approach
US6978174B2 (en) 2002-04-08 2005-12-20 Ardian, Inc. Methods and devices for renal nerve blocking
US20070129761A1 (en) 2002-04-08 2007-06-07 Ardian, Inc. Methods for treating heart arrhythmia
US8774922B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Catheter apparatuses having expandable balloons for renal neuromodulation and associated systems and methods
US9308044B2 (en) 2002-04-08 2016-04-12 Medtronic Ardian Luxembourg S.A.R.L. Methods for therapeutic renal neuromodulation
US8774913B2 (en) 2002-04-08 2014-07-08 Medtronic Ardian Luxembourg S.A.R.L. Methods and apparatus for intravasculary-induced neuromodulation
US7756583B2 (en) 2002-04-08 2010-07-13 Ardian, Inc. Methods and apparatus for intravascularly-induced neuromodulation
AU2003263466A1 (en) * 2002-09-26 2004-04-19 Pfizer Products Inc. Use of excipients to increase dna uptake by swine muscle cells
ATE465753T1 (en) 2002-10-21 2010-05-15 Eisai Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES CAUSED BY THE HUMAN PAPILLOMA VIRUS
US20050287118A1 (en) * 2003-11-26 2005-12-29 Epitomics, Inc. Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) * 2003-11-26 2005-12-15 Epitomics, Inc. High-throughput method of DNA immunogen preparation and immunization
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
CN1946838A (en) * 2003-12-23 2007-04-11 赛瑟拉公司 Definitive endoderm
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
US7541185B2 (en) * 2003-12-23 2009-06-02 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
MX2009009225A (en) 2003-12-23 2009-09-28 Cythera Inc Definitive endoderm.
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
EP2377922B1 (en) 2004-04-27 2020-04-08 Viacyte, Inc. PDX1 expressing endoderm
FR2872055B1 (en) 2004-06-24 2008-02-08 Yves Leon Scherman DEVICE FOR TRANSFERRING MOLECULES TO CELLS USING A FORCE OF PHYSICAL ORIGIN AND COMBINATION FOR IMPLEMENTING THE METHOD
CA2966883A1 (en) 2004-07-09 2006-02-16 Cythera, Inc. Methods for identifying factors for differentiating definitive endoderm
EP1791952A4 (en) * 2004-08-13 2008-06-11 Univ Georgia Res Found Compositions and methods for self-renewal and differentiation in human embryonic stem cells
US7937143B2 (en) 2004-11-02 2011-05-03 Ardian, Inc. Methods and apparatus for inducing controlled renal neuromodulation
US20070048289A1 (en) * 2005-08-31 2007-03-01 Grandjean Pierre A Cellular intervention to treat damaged myocardium
ES2743202T3 (en) 2005-10-27 2020-02-18 Viacyte Inc Endoderm of the dorsal and ventral proximal intestine expressing PDX1
US20070253969A1 (en) * 2005-11-14 2007-11-01 Freda Stevenson Materials and methods relating to DNA vaccination
US7695965B2 (en) 2006-03-02 2010-04-13 Cythera, Inc. Methods of producing pancreatic hormones
US11254916B2 (en) 2006-03-02 2022-02-22 Viacyte, Inc. Methods of making and using PDX1-positive pancreatic endoderm cells
WO2007103282A2 (en) 2006-03-02 2007-09-13 Cythera, Inc. Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
US8260411B1 (en) 2006-09-06 2012-09-04 Twin Star Medical, Inc. Conductive injection and aspiration device and method
WO2008048647A1 (en) * 2006-10-17 2008-04-24 Cythera, Inc. Modulation of the phosphatidylinositol-3-kinase pathway in the differentiation of human embryonic stem cells
WO2008118212A2 (en) 2006-11-08 2008-10-02 Veritas, Llc In vivo delivery of double stranded rna to a target cell
JP5646851B2 (en) 2006-11-17 2014-12-24 ジェネトロニクス，インコーポレイティド Method for enhancing immune response using electroporation-assisted vaccine administration and booster administration
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
PL2612868T3 (en) 2007-11-01 2018-12-31 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
AU2009231598B2 (en) 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
WO2009124312A2 (en) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
US8652129B2 (en) 2008-12-31 2014-02-18 Medtronic Ardian Luxembourg S.A.R.L. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
EP2391383B1 (en) 2009-02-02 2015-12-23 ChronTech Pharma AB Codon-optimized hepatitis b virus core antigen (hbcag)
US8207138B2 (en) 2009-05-19 2012-06-26 Medtronic, Inc. Methods and devices for improved efficiency of RNA delivery to cells
US20100298697A1 (en) * 2009-05-19 2010-11-25 Medtronic, Inc. Method and devices for improved efficiency of rna delivery to cells
WO2011032179A1 (en) 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
KR101965337B1 (en) 2009-11-02 2019-04-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
CN102770156B (en) 2009-12-16 2016-01-20 克洛恩泰克制药股份公司 Codon optimized hepatitis B virus core antigen (HBCAG)
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2011097640A1 (en) 2010-02-08 2011-08-11 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
JP6293485B2 (en) 2010-09-27 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Consensus antigen constructs and vaccines made from them, and methods of treating malaria using them
US20120237975A1 (en) 2010-10-01 2012-09-20 Jason Schrum Engineered nucleic acids and methods of use thereof
JP6046041B2 (en) 2010-10-25 2016-12-14 メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ Devices, systems, and methods for neuromodulation therapy evaluation and feedback
SI3536703T1 (en) 2010-11-12 2022-04-29 The Trustees Of The University Of Pennsylvania Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof
JP6099573B2 (en) 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Nucleic acid molecules encoding novel herpes antigens, vaccines containing them and methods of use thereof
WO2012109668A1 (en) 2011-02-11 2012-08-16 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same
US9238679B2 (en) 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2720740A1 (en) 2011-06-15 2014-04-23 ChronTech Pharma AB Injection needle and device
US9446114B2 (en) 2011-07-11 2016-09-20 Inovio Pharmaceuticals, Inc. Cross-protective arenavirus vaccines and their method of use
EP2741785B1 (en) 2011-07-12 2018-09-05 Philadelphia Health and Education Corporation Novel clostridium difficile dna vaccine
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
US9708384B2 (en) 2011-09-22 2017-07-18 The Trustees Of The University Of Pennsylvania Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
CA2850624A1 (en) 2011-10-03 2013-04-11 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
KR20220132652A (en) 2011-12-12 2022-09-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
JP6407028B2 (en) 2011-12-12 2018-10-17 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Protein containing MRSA PBP2a and fragments thereof, nucleic acid encoding the same, composition for preventing and treating MRSA infection and use thereof
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
JP2015509716A (en) 2012-02-22 2015-04-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Use of CD2 signaling domains in second generation chimeric antigen receptors
WO2013126733A1 (en) 2012-02-22 2013-08-29 The Trustees Of University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
US9750568B2 (en) 2012-03-08 2017-09-05 Medtronic Ardian Luxembourg S.A.R.L. Ovarian neuromodulation and associated systems and methods
US9510777B2 (en) 2012-03-08 2016-12-06 Medtronic Ardian Luxembourg S.A.R.L. Monitoring of neuromodulation using biomarkers
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
KR20140146651A (en) 2012-04-10 2014-12-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
EP4190350A1 (en) 2012-04-12 2023-06-07 The Trustees Of The University Of Pennsylvania Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
MX2015000426A (en) 2012-07-13 2015-07-14 Univ Pennsylvania Enhancing activity of car t cells by co-introducing a bispecific antibody.
WO2014055442A2 (en) 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US10117896B2 (en) 2012-10-05 2018-11-06 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014064534A2 (en) 2012-10-05 2014-05-01 Chrontech Pharma Ab Injection needle, device, immunogenic compositions and method of use
US20140110296A1 (en) 2012-10-19 2014-04-24 Medtronic Ardian Luxembourg S.A.R.L. Packaging for Catheter Treatment Devices and Associated Devices, Systems, and Methods
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． Chemically modified mRNA
AU2013358947B2 (en) 2012-12-13 2016-10-20 Inovio Pharmaceuticals, Inc. WT1 vaccine
KR102276405B1 (en) 2013-03-15 2021-07-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
KR20150130284A (en) 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Cancer vaccines and methods of treatment using the same
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014186409A1 (en) 2013-05-15 2014-11-20 Chrontech Pharma Ab Immunogenic compositions for inhibiting hepatitis d virus
DK3028048T3 (en) 2013-07-31 2019-01-21 Bioventures Llc COMPOSITIONS FOR TREATMENT AND PREVENTION OF CANCER TARGETING AGAINST TUMOR-ASSOCIATED CARBOHYDRATE ANTIGEN
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Polynucleotide encoding low density lipoprotein receptor
CN105829341A (en) 2013-12-13 2016-08-03 宾夕法尼亚大学理事会 DNA antibody constructs and method of using same
EP4303229A3 (en) 2014-01-21 2024-04-17 Novartis AG Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US10194980B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
US9980766B1 (en) 2014-03-28 2018-05-29 Medtronic Ardian Luxembourg S.A.R.L. Methods and systems for renal neuromodulation
US10194979B1 (en) 2014-03-28 2019-02-05 Medtronic Ardian Luxembourg S.A.R.L. Methods for catheter-based renal neuromodulation
JP6879910B2 (en) 2014-10-31 2021-06-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Modification of gene expression in CART cells and their use
CA2966035A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Compositions and methods of stimulating and expanding t cells
CN107427566B (en) 2014-12-01 2021-08-17 宾夕法尼亚大学理事会 DNA antibody constructs and methods of use thereof
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
CA3155251A1 (en) 2015-05-01 2016-11-10 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
ES2937963T3 (en) 2015-07-21 2023-04-03 Modernatx Inc Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3340998B1 (en) 2015-08-28 2023-01-11 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
WO2017055522A1 (en) 2015-09-29 2017-04-06 Academisch Medisch Centrum Stabilized env proteins of hiv
WO2017070624A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
EA201891001A1 (en) 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. VACCINES ON THE BASIS OF NUCLEIC ACIDS AGAINST WINDSHEAD VIRUS (VZV)
CA3002819A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Sexually transmitted disease vaccines
BR112018015893A2 (en) 2016-02-05 2019-03-06 Inovio Pharmaceuticals Inc cancer vaccines and treatment methods using the same
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7250520B2 (en) 2016-04-13 2023-04-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド Recombinant arterivirus replicon system and uses thereof
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
CN110073002A (en) 2016-10-17 2019-07-30 合成基因组公司 Recombinant virus replicates subsystem and application thereof
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
WO2018106615A2 (en) 2016-12-05 2018-06-14 Synthetic Genomics, Inc. Compositions and methods for enhancing gene expression
MA50335A (en) 2016-12-08 2020-08-19 Modernatx Inc NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
WO2018170260A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Respiratory syncytial virus vaccine
MA52262A (en) 2017-03-15 2020-02-19 Modernatx Inc BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
EP3672983A1 (en) 2017-08-26 2020-07-01 Academisch Medisch Centrum Improved hiv envelope glycoprotein immunogens
US10653767B2 (en) 2017-09-14 2020-05-19 Modernatx, Inc. Zika virus MRNA vaccines
JP7441169B2 (en) 2017-12-13 2024-02-29 イノビオ ファーマシューティカルズ，インコーポレイティド Cancer vaccines targeting MUC16 and their use
BR112020011443A2 (en) 2017-12-13 2020-12-01 Inovio Pharmaceuticals, Inc. nucleic acid molecule and its use, vector and its use, composition, protein and vaccine
JP7352547B2 (en) 2017-12-13 2023-09-28 イノビオ ファーマシューティカルズ，インコーポレイティド Cancer vaccines targeting mesothelin and their use
MA51312A (en) 2017-12-19 2020-10-28 Bavarian Nordic As METHODS AND COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE AGAINST THE HEPATITIS B VIRUS (HBV)
KR20200101416A (en) 2017-12-19 2020-08-27 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hepatitis B virus (HBV) vaccine and its uses
EA202091516A1 (en) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSE AGAINST HEPATITIS B VIRUS (HBV)
EA202091513A1 (en) 2017-12-19 2020-09-09 Янссен Сайенсиз Айрлэнд Анлимитед Компани VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
US11389531B2 (en) 2017-12-19 2022-07-19 Janssen Sciences Ireland Unlimited Company Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
WO2019129851A1 (en) 2017-12-29 2019-07-04 Cellectis Method for improving production of car t cells
US11083786B2 (en) 2018-01-19 2021-08-10 Janssen Pharmaceuticals, Inc. Induce and enhance immune responses using recombinant replicon systems
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US20220177863A1 (en) 2019-03-18 2022-06-09 The Broad Institute, Inc. Type vii crispr proteins and systems
CN113661180A (en) 2019-03-27 2021-11-16 宾夕法尼亚大学董事会 Tn-MUC1 Chimeric Antigen Receptor (CAR) T cell therapy
WO2020255020A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors
US20220305114A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and small molecule pdl1 or pd1 inhibitor
US20220305115A1 (en) 2019-06-18 2022-09-29 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
WO2020255009A2 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
WO2020255013A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being amide derivatives
WO2020255016A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255042A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a pyrimidine derivative
CA3140707A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives
EP3986456A1 (en) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
CA3141238A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Hepatitis b virus (hbv) vaccines and uses thereof
WO2020255019A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and a quinazoline derivative
JP2022536945A (en) 2019-06-18 2022-08-22 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Combination of hepatitis B virus (HBV) vaccine and RNAi targeting HBV
US20220233526A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020254876A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Virus-like particle delivery of hepatitis b virus (hbv) vaccines
US20220305116A1 (en) 2019-06-18 2022-09-29 Janssen Sciences lreland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and capsid assembly modulators being sulfonamide derivatives
WO2020255015A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
WO2020255035A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and pyrimidine derivatives
CN114630675A (en) 2019-06-18 2022-06-14 爱尔兰詹森科学公司 Combination of Hepatitis B Virus (HBV) vaccine and anti-PD-1 or anti-PD-L1 antibody
CA3141323A1 (en) 2019-06-18 2020-12-24 Helen Horton Recombinant interleukin 12 construct and uses thereof
WO2020255010A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of recombinant interleukin 12 construct and hepatitis b virus (hbv) vaccines
WO2020255022A1 (en) 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and aminopyridine derivatives as hpk1 inhibitors
WO2020255063A1 (en) 2019-06-20 2020-12-24 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
EP3986563A1 (en) 2019-06-20 2022-04-27 Janssen Sciences Ireland Unlimited Company Lipid nanoparticle or liposome delivery of hepatitis b virus (hbv) vaccines
US20230000543A1 (en) * 2019-11-27 2023-01-05 North Carolina State University Methods for controlling treatment volumes, thermal gradients, muscle stimulation, and immune responses in pulsed electric field treatments
CN115315446A (en) 2020-03-06 2022-11-08 Go医疗股份有限公司 anti-sugar-CD 44 antibodies and uses thereof
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3172447A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20230330211A1 (en) 2020-03-27 2023-10-19 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronaviruses
EP4165183A1 (en) 2020-06-12 2023-04-19 University of Rochester Encoding and expression of ace-trnas
AU2021303478A1 (en) 2020-07-08 2023-02-16 Janssen Sciences Ireland Unlimited Company RNA replicon vaccines against HBV
JP2023541456A (en) 2020-09-14 2023-10-02 ブイオーアール バイオファーマ インコーポレーテッド Chimeric antigen receptor for cancer treatment
WO2022097068A1 (en) 2020-11-05 2022-05-12 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
TW202245809A (en) 2020-12-18 2022-12-01 美商詹森藥物公司 Combination therapy for treating hepatitis b virus infection
EP4267740A1 (en) 2020-12-28 2023-11-01 Arcturus Therapeutics, Inc. Transcription activator-like effector nucleases (talens) targeting hbv
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
WO2023010126A2 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Chimeric antigen receptors for treatment of cancer
WO2023010118A1 (en) 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
WO2023014863A1 (en) 2021-08-05 2023-02-09 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
CA3230934A1 (en) 2021-09-03 2023-03-09 Go Therapeutics, Inc. Anti-glyco-cmet antibodies and their uses
TW202325733A (en) 2021-09-03 2023-07-01 美商Ｇｏ治療公司 Anti-glyco-lamp1 antibodies and their uses
WO2023056284A1 (en) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronavirus infection
WO2023150753A1 (en) 2022-02-07 2023-08-10 University Of Rochester Optimized sequences for enhanced trna expression or/and nonsense mutation suppression
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy
WO2023233290A1 (en) 2022-05-31 2023-12-07 Janssen Sciences Ireland Unlimited Company Rnai agents targeting pd-l1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043702A2 (en) * 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
WO1999001175A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
WO2000045823A1 (en) * 1999-02-08 2000-08-10 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0239267B2 (en) 1984-06-12 1990-09-04 Intaa Noba Kk INIONCHUNYUSHIKICHIRYOSOCHI
US4702732A (en) 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4596556A (en) * 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
NZ219392A (en) 1986-02-28 1989-05-29 Smithkline Beckman Corp Production of an immortalised primary cell line
DE68925030T2 (en) 1988-01-21 1996-07-25 Massachusetts Inst Technology MOLECULE TRANSPORT THROUGH FABRICS WITH THE USE OF ELECTROPORATION.
US5389069A (en) 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US4913699A (en) * 1988-03-14 1990-04-03 Parsons James S Disposable needleless injection system
US5501662A (en) 1992-05-22 1996-03-26 Genetronics, Inc. Implantable electroporation method and apparatus for drug and gene delivery
US5507724A (en) 1992-07-01 1996-04-16 Genetronics, Inc. Electroporation and iontophoresis apparatus and method for insertion of drugs and genes into cells
US5304120A (en) 1992-07-01 1994-04-19 Btx Inc. Electroporation method and apparatus for insertion of drugs and genes into endothelial cells
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5318514A (en) 1992-08-17 1994-06-07 Btx, Inc. Applicator for the electroporation of drugs and genes into surface cells
US5468223A (en) 1992-11-30 1995-11-21 C.N.R.S. Paris Electrochemotherapy
JP3360865B2 (en) * 1993-03-26 2003-01-07 東海旅客鉄道株式会社 Train speed control method and device
FR2703253B1 (en) 1993-03-30 1995-06-23 Centre Nat Rech Scient APPLICATOR OF ELECTRIC PULSES FOR TREATING BIOLOGICAL TISSUES.
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
IL108775A (en) 1994-02-25 2003-09-17 Univ Ramot Method for efficient incorporation of molecules into cells
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5810762A (en) 1995-04-10 1998-09-22 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
EP0769151A1 (en) 1995-05-02 1997-04-23 Koninklijke Philips Electronics N.V. Method of and device for magnetic resonance imaging of objects
US5730723A (en) * 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6041252A (en) 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
WO1997007826A1 (en) 1995-08-29 1997-03-06 Cbr Laboratories, Inc. In vivo electroporation of cells
US5944710A (en) 1996-06-24 1999-08-31 Genetronics, Inc. Electroporation-mediated intravascular delivery
WO1998027966A2 (en) 1996-12-23 1998-07-02 Bavarian Nordic Research Institute A/S Encapsulated cells producing antibodies
FR2758569B1 (en) 1997-01-20 1999-04-02 Centre Nat Rech Scient BIOLOGICAL MATERIAL FOR THE TREATMENT OF A MAMMAL BY TRANSFERRING ANTIBODY GENE AND PHARMACEUTICAL COMPOSITION CONCERNING THE SAME
US20020168339A1 (en) * 1997-01-20 2002-11-14 Marc Piechaczyk Biological material for treating a mammal by antibody gene transfer and pharmaceutical composition containing same
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
KR20010020570A (en) 1997-06-30 2001-03-15 자끄 사비나 Improved method for transferring nucleic acid into multicelled eukaryotic organism cells and combination therefor
US5965925A (en) 1997-10-22 1999-10-12 Artisan Components, Inc. Integrated circuit layout methods and layout structures
US6009347A (en) 1998-01-27 1999-12-28 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6440944B2 (en) * 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
US20030018006A1 (en) 2001-06-29 2003-01-23 Academia Sinica In vivo electroporation-mediated cytokine/immunocytokine-based antitumoral gene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043702A2 (en) * 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
WO1999001175A1 (en) * 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
WO2000045823A1 (en) * 1999-02-08 2000-08-10 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BACHY MONIQUE ET AL: "Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse.", VACCINE, vol. 19, no. 13-14, 8 February 2001 (2001-02-08), pages 1688 - 1693, XP002183367, ISSN: 0264-410X *
BIOELECTROCHEMISTRY AND BIOENERGETICS, vol. 49, no. 1, October 1999 (1999-10-01), pages 11 - 20, ISSN: 0302-4598 *
CURR OPIN MOL THER, (2000 APR) 2 (2) 150-4. REF: 39 *
DANKO I ET AL: "PHARMACOLOGICAL ENHANCEMENT OF IN VIVO FOREIGN GENE EXPRESSION IN MUSCLE", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 1, no. 2, March 1994 (1994-03-01), pages 114 - 121, XP001030901, ISSN: 0969-7128 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 20 January 1998 (1998-01-20), LE BORGNE SYLVIE ET AL: "In vivo induction of specific cytotoxic T lymphocytes in mice and rhesus macaques immunized with DNA vector encoding an HIV epitope fused with hepatitis B surface antigen.", XP002183372, Database accession no. PREV199800126231 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 2000, SELBY MARK ET AL: "Enhancement of DNA vaccine potency by electroporation in vivo.", XP002183376, Database accession no. PREV200000467774 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1999 (1999-04-01), MATHIESEN I: "Electropermeabilization of skeletal muscle enhances gene transfer in vivo.", XP002183374, Database accession no. PREV199900227202 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), SIN JEONG-IM ET AL: "DNA priming-protein boosting enhances both antigen-specific antibody and Th1-type cellular immune responses in a murine herpes simplex virus-2 gD vaccine model.", XP002183371, Database accession no. PREV200000068151 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), ZEWERT THOMAS E ET AL: "Creation of transdermal pathways for macromolecule transport by skin electroporation and a low toxicity, pathway enlarging molecule.", XP002183373, Database accession no. PREV200000412516 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; SMITH L C ET AL: "Advances in plasmid gene delivery and expression in skeletal muscle.", XP002183375, retrieved from STN Database accession no. 2001206600 *
DNA AND CELL BIOLOGY, vol. 18, no. 10, October 1999 (1999-10-01), pages 771 - 779, ISSN: 1044-5498 *
GENE THERAPY, vol. 6, no. 4, April 1999 (1999-04-01), pages 508 - 514, ISSN: 0969-7128 *
JOURNAL OF BIOTECHNOLOGY, vol. 83, no. 1-2, 2000, pages 147 - 152, ISSN: 0168-1656 *
KADOWAKI SHIN-ETSU ET AL: "Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.", VACCINE, vol. 18, no. 25, 2000, pages 2779 - 2788, XP002183369, ISSN: 0264-410X *
MENDIRATTA SANJEEV KUMAR ET AL: "Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.", CANCER RESEARCH, vol. 61, no. 3, 1 February 2001 (2001-02-01), pages 859 - 863, XP002183368, ISSN: 0008-5472 *
VIROLOGY, vol. 240, no. 2, 20 January 1998 (1998-01-20), pages 304 - 315, ISSN: 0042-6822 *
ZUCCHELLI S ET AL: "Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.", JOURNAL OF VIROLOGY, (2000 DEC) 74 (24) 11598-607., XP002183370 *

Also Published As

Publication number Publication date
US20060041219A1 (en) 2006-02-23
WO2001085202A2 (en) 2001-11-15
US20030065362A1 (en) 2003-04-03
US6610044B2 (en) 2003-08-26
US6958060B2 (en) 2005-10-25
US20040092907A1 (en) 2004-05-13
US6261281B1 (en) 2001-07-17
AU5493201A (en) 2001-11-20
US20080147131A1 (en) 2008-06-19
US20020038112A1 (en) 2002-03-28
EP1280550A2 (en) 2003-02-05
US7931640B2 (en) 2011-04-26

Similar Documents

Publication Publication Date Title
WO2001085202A3 (en) Electroporation for introduction of molecules into cells
PL337583A1 (en) Improved method of transferring nucleic acid to a striated muscle and connection enabling accomplishment of this method
DE69830178D1 (en) COMPOSITION OF MIXTURES IN VAGAL-INDUCED ASYSTOLIA
DE69728057D1 (en) IONTOPHORETIC TRIGGERABLE DELIVERY DEVICE TO REDUCE ELECTRICAL SENSITIVES
AU2001234857A1 (en) Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo
DE3369466D1 (en) Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
AU6320690A (en) Defibrillation method and apparatus
ATE246103T1 (en) GROUND POWER SUPPLY FOR AN ELECTRIC VEHICLE WITH GROUND CONNECTION DEVICE
EP1034188A4 (en) Method of designing agonists and antagonists to igf receptor
WO2002068040A3 (en) Apparatus for stimulating a muscle of a subject
AU2001245852A1 (en) Stimulatory device and methods to electrically stimulate the phrenic nerve
WO1998021343A8 (en) Genes encoding telomerase proteins
DE69414686T2 (en) ELECTRICAL CONNECTING STRUCTURE AND METHOD FOR ELECTRICALLY CONNECTING CONNECTIONS TO EACH OTHER
IT8819023A0 (en) CARRY OUT METHOD AND EQUIPMENT FOR SERIES AND PHASE BOLT CONNECTIONS IN AN ELECTRIC GENERATOR.
IL149744A0 (en) A body formed of set, initially pasty material and including an electrically conducting path and a method of making such a body
AU3162097A (en) Retinoid metabolizing protein
ZA9810944B (en) Insulated electrical conductor and contacting method.
WO1987007472A3 (en) A dna sequence encoding the mas oncogene, polypeptides encoded therefrom, and diagnostic and other methods based thereon
HK1025125A1 (en) The neurotrophic factor nnt-1.
DE68918933T2 (en) Electrical connector with preloaded contacts and process for its manufacture.
ATA138388A (en) CONCRETE FOUNDATION FOR STEEL POLES OF ELECTRICAL HIGH VOLTAGE PIPES, SKI LIFTS AND THE LIKE
WO2002018575A3 (en) Genes expressed in the cell cycle
WO1998052613A3 (en) Method of administration for a therapeutic agent utilizing suitable forms of hyaluronic acid and combinations with electroporation
IL122626A0 (en) Nucleic acids encoding hev structural proteins hev structural proteins encoded thereby and uses thereof
PT93934A (en) Device and method for the iontophoretic release of drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001928065

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001928065

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001928065

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP